Article,
Tumor suppressor genes and their interactions and neo-adjuvant therapy in paclitaxel resistance in cancer
World Journal of Biology Pharmacy and Health Sciences, 14 (1): 069–079 (April 2023)
DOI: 10.30574/wjbphs.2023.14.1.0158
Abstract
Paclitaxel (PTX) is a drug that is often used in the treatment of solid tumours. However, PTX resistance is a significant impediment to cancer therapy. Exploration of drug resistance mechanisms reveals that tumour suppressor genes (TSGs) play a critical role in chemotherapeutic drug responsiveness. TSGs, a group of genes that are frequently inactivated in cancer, have the ability to control a variety of biological processes. A systematic study of paclitaxel and paclitaxel-containing chemotherapy regimens for advanced gastric cancer was conducted. Response rates, median progression-free survivals, and median overall survivals were studied, as well as the treatment regimens and patient numbers in each study. Taxanes, which are suggested in the adjuvant environment, are also taken into account in the neoadjuvant setting. There were twenty studies using nab-paclitaxel in the neoadjuvant context found. In the neoadjuvant treatment of breast cancer, nab-Paclitaxel displayed anticancer efficacy and a tolerable safety profile. Current and upcoming trials will assess preoperative nab-paclitaxel in breast cancer, including in conjunction with a variety of new immune targeted treatments.
